These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26886324)

  • 1. Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events.
    Kotarek J; Stuart C; De Paoli SH; Simak J; Lin TL; Gao Y; Ovanesov M; Liang Y; Scott D; Brown J; Bai Y; Metcalfe DD; Marszal E; Ragheb JA
    J Pharm Sci; 2016 Mar; 105(3):1023-7. PubMed ID: 26886324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.
    Daniels AL; Randolph TW
    J Pharm Sci; 2018 May; 107(5):1313-1321. PubMed ID: 29409840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Watch out for a revival of peginesatide in sports.
    Jelkmann W
    Drug Test Anal; 2017 Feb; 9(2):157-160. PubMed ID: 27279382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
    Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
    J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product.
    Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P
    J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins.
    Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF
    J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics.
    Depaz RA; Chevolleau T; Jouffray S; Narwal R; Dimitrova MN
    J Pharm Sci; 2014 May; 103(5):1384-93. PubMed ID: 24643773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of subvisible particles in therapeutic proteins.
    Singh SK; Toler MR
    Methods Mol Biol; 2012; 899():379-401. PubMed ID: 22735966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of protein particles in parenteral solutions using micro-flow imaging.
    Huang CT; Sharma D; Oma P; Krishnamurthy R
    J Pharm Sci; 2009 Sep; 98(9):3058-71. PubMed ID: 18937372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
    Singh SK; Afonina N; Awwad M; Bechtold-Peters K; Blue JT; Chou D; Cromwell M; Krause HJ; Mahler HC; Meyer BK; Narhi L; Nesta DP; Spitznagel T
    J Pharm Sci; 2010 Aug; 99(8):3302-21. PubMed ID: 20310025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential clinical relevance of visible particles in parenteral drugs.
    Doessegger L; Mahler HC; Szczesny P; Rockstroh H; Kallmeyer G; Langenkamp A; Herrmann J; Famulare J
    J Pharm Sci; 2012 Aug; 101(8):2635-44. PubMed ID: 22628244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
    Sharma DK; Oma P; Pollo MJ; Sukumar M
    J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginesatide in patients with anemia undergoing hemodialysis.
    Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
    N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of subvisible particles in human immunoglobulin and lipid nanoparticles repackaged from a multi-dose vial using plastic syringes.
    Hada S; Na KJ; Jeong J; Choi DH; Kim NA; Jeong SH
    Int J Biol Macromol; 2023 Mar; 232():123439. PubMed ID: 36716845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.
    Nayak A; Colandene J; Bradford V; Perkins M
    J Pharm Sci; 2011 Oct; 100(10):4198-204. PubMed ID: 21698601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.